10-Q: Acutus Medical Reports Q1 2024 Results Amidst Strategic Shift and Nasdaq Delisting

Acutus Medical's Q1 2024 results reflect a strategic realignment towards manufacturing for Medtronic, alongside a Nasdaq delisting and a shift to OTC trading.

Summary

• Acutus Medical reported a net loss of $1.62 million for the first quarter of 2024, compared to a net loss of $16.315 million in the same period last year.
• The company's revenue increased to $3.625 million, up from $1.242 million in Q1 2023, primarily due to increased sales of left-heart access products to Medtronic.
• The company has undergone a strategic restructuring, winding down its mapping and ablation business to focus on manufacturing for Medtronic.
• Discontinued operations generated a net income of $0.435 million in Q1 2024, compared to a net loss of $12.035 million in Q1 2023.
• The company's cash, cash equivalents, restricted cash, and marketable securities totaled $20 million as of March 31, 2024, down from $29.4 million at the end of 2023.
• Acutus Medical's stock was delisted from Nasdaq on May 9, 2024, and now trades on the OTC Pink Sheets under the symbol AFIB.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is significant revenue growth and a turnaround in discontinued operations, the delisting from Nasdaq, continued net losses, and reliance on a single partner create substantial risks and uncertainties. The sentiment is cautiously negative.

Positives

• Revenue from continuing operations increased significantly due to the Medtronic partnership.
• The company achieved a net income from discontinued operations, a substantial turnaround from the previous year.
• The strategic restructuring is expected to reduce operating expenses and optimize cash resources.
• The company has secured a manufacturing and distribution agreement with Medtronic for its left-heart access products.
• Acutus Medical recognized a gain of $2.8 million related to Medtronic's left-heart access net sales earn-outs.

Negatives

• The company reported a net loss of $1.62 million for the quarter.
• Acutus Medical's stock was delisted from Nasdaq due to non-compliance with listing rules.
• The company has incurred significant operating losses and negative cash flows since its inception.
• The company is now solely reliant on Medtronic for revenue generation and market success of the left-heart access products.
• The company has an accumulated deficit of $601.6 million.

Risks

• The company is heavily reliant on Medtronic for revenue, and any disruption in this partnership could significantly impact its financial performance.
• The company faces risks related to manufacturing and supply chain disruptions.
• The company may not achieve the anticipated cost savings or other benefits from the restructuring.
• The company faces intense competition in the medical device industry.
• The company's financial results may fluctuate due to various factors, including inventory write-offs and changes in raw material costs.
• The company is subject to legal proceedings, including a securities class action lawsuit and an arbitration demand from Biotronik.
• The company's ability to raise additional capital through equity or debt financing is uncertain.

Future Outlook

Management believes the company's current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months. The company will rely on its strategic partnership with Medtronic to generate revenue through manufacturing and potential earnouts. The company will continue to review operations to optimize the business.

Management Comments

• Management believes the company's current cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months from the date of this filing.
• Management continues to review cost improvement opportunities and pathways to reduce expenses and cash burn, while preserving the resources to invest in future growth.

Industry Context

The strategic shift towards manufacturing for Medtronic reflects a trend in the medical device industry where companies are focusing on core competencies and strategic partnerships. The delisting from Nasdaq and move to OTC trading highlights the challenges faced by smaller companies in maintaining compliance with exchange requirements.

Comparison to Industry Standards

• Acutus Medical's revenue growth of 192% year-over-year is significant, but it is important to note that this is from a low base and is primarily driven by the Medtronic partnership.
• The company's negative gross margin of 1% in Q1 2024, while an improvement from -70% in Q1 2023, still indicates challenges in cost management compared to established medical device manufacturers.
• The company's reliance on a single partner, Medtronic, for revenue generation is a significant risk compared to companies with diversified revenue streams.
• The delisting from Nasdaq is a major setback, as it reduces the company's visibility and access to capital markets, unlike its larger, publicly traded competitors such as Medtronic, Abbott, and Boston Scientific.
• The company's accumulated deficit of $601.6 million is substantial and highlights the challenges in achieving profitability, which is a common issue for early-stage medical device companies.

Legal Proceedings

• The company and certain of its current and former officers have been named as defendants in two putative securities class action lawsuits, which were dismissed by the court on April 29, 2024, but the plaintiff has 30 days to file an appeal.
• Biotronik has filed a Demand for Arbitration against Acutus Medical, alleging breach of contractual obligations, seeking $38 million in damages.

Related Party Transactions

• The company has a consulting agreement with the former chairman of the Board of Directors.
• The company has a credit agreement with related parties Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.

Stakeholder Impact

• Shareholders have experienced a significant loss in value due to the delisting from Nasdaq.
• Employees have been impacted by the workforce reduction as part of the restructuring.
• Customers of the mapping and ablation products will no longer be supported by Acutus Medical.
• Suppliers may be affected by the company's shift in business model.
• Creditors are exposed to the company's financial risks and debt obligations.

Next Steps

• The company will focus on manufacturing and distributing left-heart access products for Medtronic.
• The company will seek to establish relationships with market makers to provide additional trading opportunities in its shares on the OTC Pink Sheets.
• The company will continue to review operations to optimize the business and reduce expenses.
• The company will defend itself vigorously against the Biotronik arbitration demand.

Key Dates

Keywords

Acutus Medical, Medtronic, left-heart access, restructuring, Nasdaq delisting, OTC Pink Sheets, manufacturing, medical devices, financial results, earnouts